XOMA (XOMA) Stock Forecast & Price Target

XOMA Royalty is expected to continue growth through the acquisition of early to mid-stages clinical assets, with a strong focus on key products such as Vabysmo, Ojemda, and Miplyffa. The company has shown a sustained profitability and well-managed OPEX, with year-end cash of $83 million (excluding restricted cash). XOMA also has a strong cash position of $130.6 million, allowing them to leverage further deals in the future. Their in vivo evidence and animal studies have shown long-term expression of COL7, which is a positive indication for their product FCX-007. Additionally, XOMA's expanded relationship with Takeda brings in nine new assets and strengthens their overall portfolio. Despite recent negative news on some assets, XOMA's diversified risk profile and growing number of assets give them a strong downside buffer and potential for further valuation upside.

XOMA Royalty is set to see a negative financial impact due to an increase in share count and diluted EPS, despite the potential boost from mezagitamab's differentiated mechanism of action and projected 5.5% royalty rate. Challenges in ITP and IgAN markets from competitors and the requirement for differentiation could lead to a limited market share for mezagitamab, making it critical for its commercial success. Furthermore, while XOMA recently expanded its royalty opportunity for mezagitamab, the undisclosed increase in royalty is estimated to be only 1.5%, and XOMA is also entitled to milestone payments from Takeda.